Molecular Mechanisms of Metastasis in Prostate Cancer

Overview

Journal Asian J Androl

Specialty Urology

Date 2008 Dec 4

PMID 19050684

Citations 45

Authors

Noel W Clarke

Claire A Hart

Mick D Brown

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) preferentially metastasizes to the bone marrow stroma of the axial skeleton. This activity is the principal cause of PCa morbidity and mortality. The exact mechanism of PCa metastasis is currently unknown, although considerable progress has been made in determining the key players in this process. In this review, we present the current understanding of the molecular processes driving PCa metastasis to the bone.

Citing Articles

Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).

Xu Y, Zhang G, Liu Y, Liu Y, Tian A, Che J Int J Oncol. 2024; 65(5).

PMID: 39301646 PMC: 11419411. DOI: 10.3892/ijo.2024.5692.

Incidence of exclusive extrapelvic skeletal metastasis in prostate carcinoma on bone scintigraphy.

Singh P, Agrawal K, Rahman A, Singhal T, Parida G, Gnanasegaran G World J Radiol. 2024; 16(7):265-273.

PMID: 39086611 PMC: 11287433. DOI: 10.4329/wjr.v16.i7.265.

Nanoribbon Biosensor-Based Detection of microRNA Markers of Prostate Cancer.

Ivanov Y, Malsagova K, Goldaeva K, Kapustina S, Pleshakova T, Popov V Sensors (Basel). 2023; 23(17).

PMID: 37687982 PMC: 10490786. DOI: 10.3390/s23177527.

scTIGER: A Deep-Learning Method for Inferring Gene Regulatory Networks from Case versus Control scRNA-seq Datasets.

Dautle M, Zhang S, Chen Y Int J Mol Sci. 2023; 24(17).

PMID: 37686146 PMC: 10488287. DOI: 10.3390/ijms241713339.

Animal models of bone metastatic prostate cancer.

Tae J, Chang I Investig Clin Urol. 2023; 64(3):219-228.

PMID: 37341002 PMC: 10172043. DOI: 10.4111/icu.20230026.

References

Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P . Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004; 111(5):783-91. DOI: 10.1002/ijc.20314. View

Brown M, Hart C, Gazi E, Bagley S, Clarke N . Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br J Cancer. 2006; 94(6):842-53. PMC: 2361380. DOI: 10.1038/sj.bjc.6603030. View

Nagle R, KNOX J, Wolf C, Bowden G, Cress A . Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl. 1994; 19:232-7. View

Iwamura M, Hellman J, COCKETT A, Lilja H, Gershagen S . Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology. 1996; 48(2):317-25. DOI: 10.1016/S0090-4295(96)00182-3. View

Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A . Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003; 101(8):3126-35. DOI: 10.1182/blood-2002-08-2640. View

Montague R, Hart C, George N, Ramani V, Brown M, Clarke N . Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol. 2004; 46(3):389-401. DOI: 10.1016/j.eururo.2004.04.022. View

COOK G, Watson F . Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol. 1968; 99(1):87-96. DOI: 10.1016/S0022-5347(17)62647-8. View

Nelson J, Nguyen S, Wu-Wong J, Opgenorth T, Dixon D, Chung L . New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999; 53(5):1063-9. DOI: 10.1016/s0090-4295(98)00658-x. View

Lang S, Clarke N, George N, ALLEN T, Testa N . Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate. 1998; 34(3):203-13. DOI: 10.1002/(sici)1097-0045(19980215)34:3<203::aid-pros8>3.0.co;2-i. View

10.

Clarke N, McClure J, George N . Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991; 68(1):74-80. DOI: 10.1111/j.1464-410x.1991.tb15260.x. View

11.

Nelson J, Hedican S, George D, Reddi A, Piantadosi S, Eisenberger M . Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1(9):944-9. DOI: 10.1038/nm0995-944. View

12.

Murant S, Handley J, Stower M, Reid N, Cussenot O, Maitland N . Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer. 1997; 33(2):263-71. DOI: 10.1016/s0959-8049(96)00418-2. View

13.

Perl A, Wilgenbus P, Dahl U, Semb H, Christofori G . A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392(6672):190-3. DOI: 10.1038/32433. View

14.

Lang S, Clarke N, George N, Testa N . Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis. 1997; 15(3):218-27. DOI: 10.1023/a:1018465213641. View

15.

Lokeshwar B, Selzer M, Block N . Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 1993; 53(19):4493-8. View

16.

Trikha M, Raso E, Cai Y, Fazakas Z, Paku S, Porter A . Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate. 1998; 35(3):185-92. DOI: 10.1002/(sici)1097-0045(19980515)35:3<185::aid-pros4>3.0.co;2-g. View

17.

Umbas R, Schalken J, Aalders T, Carter B, Karthaus H, Schaafsma H . Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992; 52(18):5104-9. View

18.

Clarke N, McClure J, George N . Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol. 1993; 24(2):286-90. DOI: 10.1159/000474311. View

19.

Urwin G, Percival R, Harris S, Beneton M, Williams J, Kanis J . Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985; 57(6):721-3. DOI: 10.1111/j.1464-410x.1985.tb07040.x. View

20.

Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S . Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000; 6(9):3530-5. View